Moving targets that drive cancer progression

New England Journal of Medicine

Volumn 363, Issue 9, 2010, Pages 885-886

  Shackleton, Mark ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE;

CANCER CELL CULTURE; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; DISEASE COURSE; EPIGENETICS; GENE EXPRESSION; GENE MUTATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FAMILY; SHORT SURVEY;

EID: 77956045047     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcibr1006328     Document Type: Short Survey

References (5)

1. Roesch A, Fukunaga-Kalabis M, Schmidt EC, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010;141:583-94.
2. Nowell PC. The clonal evolution of tumor cell populations. Science 1976;194:23-8.
3. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001;414:105-11.
4. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84.
5. Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 2010;141:69-80.